Table 2.
Baseline and follow-up HbA1c, CGM-derived glucose metrics (uncorrected changes), and patient-reported outcome measure scores
| n § | Baseline | Follow-up | Change (95% CI) | P * | |
|---|---|---|---|---|---|
| HbA1c | |||||
| mmol/mol | 436 | 78.9 ± 9.1 | 62.1 ± 9.1 | −16.7 (−15.8, −17.6) | <0.001 |
| % | 436 | 9.4 ± 0.8 | 7.8 ± 0.8 | −1.5 (−1.4, −1.6) | <0.001 |
| Glucose data | |||||
| TAR, level 2 (>250 mg/dL), % | 407 | 37.2 ± 19.1 | 14.9 ± 11.8 | −22.4 (−20.5, −24.2) | <0.001 |
| TAR, level 1 (181–250 mg/dL),# % | 381 | 26.8 ± 10.3 | 22.3 ± 11.7 | −4.5 (−3.0, −6.1) | <0.001 |
| TIR (70–180 mg/dL),# % | 417 | 34.2 ± 14.5 | 61.9 ± 13.1 | 27.8 (26.2, 29.4) | <0.001 |
| TBR (54–69 mg/dL),# % | 411 | 1.8 ± 2.4 | 1.3 ± 1.6 | −0.5 (0.2, 0.8) | <0.001 |
| TBR (<54 mg/dL),# % | 397 | 0.37 ± 1.00 | 0.35 ± 0.57 | −0.03 (−0.13, 0.18) | 0.729 |
| Coefficient of variation# | 325 | 38.0 ± 6.9 | 35.2 ± 6.7 | −2.8 (−1.9, −3.6) | <0.001 |
| Patient-reported outcome measures | |||||
| Gold score | 415 | 2.3 ± 1.4 | 1.9 ± 1.2 | −0.4 (−0.2, −0.5) | <0.001 |
| Diabetes distress score | 412 | 3.3 ± 1.3 | 2.2 ± 1.0 | −1.1 (−1.0, −1.3) | <0.001 |
| Diabetes distress score (average ≥3),† % (n) | 412 | 69.2 (285) | 22.8 (94) | −46.4 (−191) | <0.001 |
| Impaired awareness of hypoglycemia (Gold score ≥4), % (n) | 415 | 16.9 (70) | 9.4 (39) | −7.5 (−31) | <0.001 |
Data are mean ± SD unless otherwise indicated. TAR, time above range.
*
Statistical significance calculated using unpaired t tests for all covariates included in this table, following assessment for skew.
†
Statistical significance calculated using Chi-squared tests.
§
Number with available paired data at baseline and follow-up included in analysis for a given outcome; total cohort = 520.
#
Data derived from isCGM at baseline and real-time CGM at follow-up.